¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"leukotriene receptor antagonist"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® receptor ÇÑ±Û ¼ö¿ëü
¼³¸í   
  ¼¼Æ÷Áú³» ¶Ç´Â ¼¼Æ÷Ç¥¸é¿¡ Á¸ÀçÇϴ ºÐÀÚ±¸Á¶·Î¼­ Æ¯À̹°Áú°ú ¼±ÅÃÀûÀ¸·Î °áÇÕÇϸ砰áÇÕ¿¡ ÀÇÇØ Æ¯ÀÌÇÑ »ý¸®Àû ÀÛ¿ëÀ» ³ªÅ¸³½´Ù. ÆéƼµåÈ£¸£¸ó, ½Å°æÀü´Þ¹°Áú, Ç׿ø, º¸Ã¼, ¸é¿ª±Û·ÎºÒ¸°¿¡ ´ëÇÑ ¼¼Æ÷Ç¥¸é ¼ö¿ëü¿Í ½ºÅ×·ÎÀ̵忡 ´ëÇÑ ¼¼Æ÷Áú³» ¼ö¿ëü°¡ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukotriene
    ·ùÄÚÆ®¸®¿£
  • antagonist
    1. ´ëÇ×Á¦, ±æÇ×Á¦ 2. ´ëÇ×±Ù
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦, ¾Æµå·¹³¯¸°±æÇ×Á¦
  • competitive antagonist
    °æÀï´ëÇ×Á¦
  • contralateral antagonist
    ¹Ý´ëÂÊ´ëÇ×±Ù
  • direct antagonist
    Á÷Á¢´ëÇ×±Ù
  • dopaminergic antagonist
    µµÆÄ¹Î´ëÇ×Á¦, µµÆÄ¹Î±æÇ×Á¦
  • muscarinic antagonist
    ¹«½ºÄ«¸°´ëÇ×Á¦
  • narcotic antagonist
    ¸¶¾à´ëÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±Ù(À°)´ëÇ×Á¦
  • opioid antagonist
    ¾ÆÆíÀ¯»çÁ¦´ëÇ×Á¦
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    1.´ëÇ×Á¦, ±æÇ×Á¦, 2.´ëÇ×±Ù
  • leukotriene
    ·ùÄÚÆ®¸®¿£
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor
    ¼ö¿ëü, ¼ö¿ë±â
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • opiate receptor
    ¾ÆÆí¼ö¿ëü
  • sensory receptor
    °¨°¢¼ö¿ëü
  • receptor site
    ¼ö¿ëüºÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukotriene
    ·ùÄÚÆ®¸®¿£
  • antagonist
    ´ëÇ×Á¦, ¸Â¹öÆÀÁ¦
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦
  • competitive antagonist
    °æÀï´ëÇ×¹°Áú
  • contralateral antagonist
    ¹Ý´ëÂÊ´ëÇ×±Ù
  • direct antagonist
    Á÷Á¢´ëÇ×±Ù
  • dopaminergic antagonist
    µµÆÄ¹Î´ëÇ×Á¦, µµÆÄ¹Î¸Â¹öÆÀÁ¦
  • ipsilateral antagonist
    °°ÀºÂÊ´ëÇ×±Ù
  • muscarinic antagonist
    ¹«½ºÄ«¸°´ëÇ×Á¦
  • narcotic antagonist
    ¸¶¾à´ëÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±ÙÀ°´ëÇ×Á¦
  • opioid antagonist
    ¾ÆÆíÀ¯»ç¹°Áú´ëÇ×Á¦
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ¾Èµå·Î°Õ¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • H2 receptor antagonist
    H2 ¼ö¿ëü ±æÇ×Á¦µé
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic antagonist
    ¾ËÆÄ¾Æµå·¹³¯¸°±æÇ×Á¦
  • androgen antagonist
    ³²¼ºÈ£¸£¸ó ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú, ±æÇ×±Ù, ±æÇ×¾à.
  • heavy metal antagonist
    Á߱ݼӱæÇ×¾à(̡˻ËÛ˻̰Ëâ).
  • heavy metal antagonist
    Á߱ݼӱæÇ×¾à(ñìÐÝáÕÑÏù÷å·).
  • A1 receptor
    A1 ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • A2 receptor
    A2 ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • CR1 => complement receptor 1
    º¸Ã¼¼ö¿ëü 1
  • CR2 => complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • CR3 => complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • CR4 => complement receptor 4
    º¸Ã¼¼ö¿ëü 4
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • benzodiazepine receptor antagonist(s)
    º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ ¼ö¿ëü ±æÇ×Á¦
  • dopamine receptor antagonist
    µµÆÄ¹Î ¼ö¿ëü ±æÇ×Á¦
  • leukotriene
    ·ùÄÚÆ®¸®¿£.
  • leukotriene
    ·ùÄÚÆ®¸®¿£, Leukotriene
  • leukotriene (LT)
    ·ùÄÚÆ®¸®¿£
  • adrenergic antagonist
    ¾Æµå·¹³¯¸° ±æÇ×¹°Áú
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°¼º ±æÇ×Á¦
  • alpha-adrenergic antagonist
    ¾ËÆÄ¾Æµå·¹³¯¸°±æÇ×Á¦
  • androgen antagonist
    ³²¼ºÈ£¸£¸ó ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú, ±æÇ×±Ù, ±æÇ×¾à.
  • antagonist
    ±æÇ×Á¦
  • associated antagonist
    °ø¾×±æÇ×¹°Áú.
  • beta-adrenergic antagonist
    º£Å¸ ¾Æµå·¹³¯¸°¼º ÀúÇØÁ¦
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Receptor
    ¼ö¿ë±â
    [¿¾ ¿ë¾î] ¼ö¿ë±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukotriene
    ·çÄÚÆ®¸®¿£
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • cholinergic antagonist
    Äݸ°±æÇ×Á¦(ÑÏù÷ð¥)
  • gibberellin antagonist
    Áö¹ö·¼¸° ±æÇ×Á¦(ÑÏù÷ð¥)
  • irreversible antagonist
    ºñ°¡¿ª ±æÇ×Á¦(ުʦæ½ÑÏù÷ð¥)
  • metabolic antagonist
    ´ë»ç¼º ±æÇ×Á¦(ÓÛÞóàõÑÏùòð¥))
  • adrenergic receptor
    ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) ¼ö¿ëü(áôé»ô÷)
  • alpha adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³ª¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷)
  • alpha receptor
    ¾ËÆÄ¼ö¿ëü(áôé»ô÷)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
  • beta receptor
    º£Å¸ ¼ö¿ëü(áôé»ô÷)
  • cyclic AMP receptor protein
    °í¸®AMP ¼ö¿ëü ´Ü¹éÁú(áôé»ô÷Ó±ÛÜòõ)
  • dopamine adrenergic receptor
    "µµÆÄ¹Î ¾Æµå·¹³¯¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷), (ÔÒ) adrenergic receptor"
  • Ehrlich's receptor theory
    ¿¡¸¦¸®È÷ ¼ö¿ëüÀÌ·Ð(áôé»ô÷×âÖå)
  • Fc receptor
    Fc ¼ö¿ëü(áôé»ô÷)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú
  • receptor
    ¼ö¿ë±â, ¼ö¿ëü, °¨¼öü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
antag antagonist
CA anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can...
FAA folic acid antagonist; formaldehyde, acetic acid, alcohol
ER efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re...
RAR rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LTRA Leukotriene receptor antagonists
H2-RA Histamine-2 receptor antagonist
IL 1ra IL 1 receptor antagonist
IRAP IL 1 receptor antagonist protein
IL-1ra Interleukin 1 receptor antagonist
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • 5-HT1 receptor antagonist
    5-HT1 ¼ö¿ë±â ±æÇ×Á¦
    ÀÏÂïÀÌ 5-hydroxytry
  • leukotriene
    ·ùÄÚÆ®¶óÀÌÀÎ, ·ùÄÚÆ®¸®¾Ø
    20°³ÀÇ Åº¼Ò¸¦ °¡Áö´Â Á÷¼âÀÇ Ä«¸£º¹½Ç»êÀ¸·Î, 1~2°³ÀÇ »ê¼Ò ġȯ°ú 3°³ ÀÌ»óÀÇ ÀÌÁß °áÇÕÀ» °¡Áö´Â »ý¹°ÇÐÀû Ȱ¼ºÀÎ È­ÇÕ¹° ±ºÀÇ ÇϳªÀÌ´Ù. ¾Æ¶ó۵·»ê¿¡¼­ºÎÅÍ ¸®Æø½ÃÁö³×À̽º °æ·Î·Î »ý¼ºµÇ¸ç, ¾Ë·¯Áö ¹× ¿°Áõ¼º ¹ÝÀÀÀÇ Á¶Àý ÀÎÀڷμ­ ±â´ÉÀ» ÇÑ´Ù. ·ùÄÚÆ®¶óÀÌÀÎÀº A, B, C, D, E µîÀÌ È®ÀεǾú°í, È­ÇÐ ±¸Á¶»ó ÀÌÁß °áÇÕÀÇ ¼ö¿¡ µû¶ó ÇϺΠ¼ýÀÚ¸¦ ±âÀçÇÑ´Ù.
  • leukotriene B4
    ·ùÄÚÆ®¶óÀÌÀÎ B4
    ¾Ë·¯Áö ¹× ¿°Áõ¼º ¹ÝÀÀÀÇ Á¶Àý ÀÎÀÚ·Î ¹éÇ÷±¸ÀÇ ¿îµ¿À» Ç×Áø½ÃŲ´Ù.
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦, ±æÇ× ¹°Áú, ±æÇ×±Ù, ±æÇ× ¾à
    ¹Ý´ë¾î=agonist. µ¿±Ù±ºÀ̳ª ÁÖµÈ ¿îµ¿±Ù¿¡ ¹Ý´ëµÇ´Â ±â´ÉÀ» ÇÏ´Â ±ÙÀ°. ¾à¸®Çп¡¼­´Â ´Ù¸¥ ¾à¹°ÀÇ È¿´ÉÀ» °¨¼Ò½ÃŰ´Â ¾à¹°À̳ª µ¿ÀÏÇÑ ¼ö¿ë±â¸¦ ÀÚ±ØÇÏ¿© »ý¼ºÇÏ´Â ¹°ÁúÀ» ÀǹÌÇÑ´Ù. ´Ù¸¥ ¾à¹°, ¹°ÁúÀÇ ÀÛ¿ëÀ» »ý¹°ÇÐÀû ¹ÝÀÀÀ» À¯µµÇÏÁö ¾Ê°í ¼¼Æ÷ ¸®¼ÁÅÍ¿¡ °áÇÕÇÏ¿©, °¨¾à ¶Ç´Â ¹«È¿·Î ÇÏ´Â ¾à¹°, ¹°Áú.
  • antagonist tooth
    ´ëÇÕÄ¡
  • competitive antagonist
    °æÀï ±æÇ× ¹°Áú
  • enzymic antagonist
    È¿¼Ò ±æÇ×Á¦
  • folic acid antagonist
    ¿±»ê ±æÇ×Á¦
  • hormone antagonist
    Ç×È£¸£¸ó ¾à, Ç×È£¸£¸ó ¹°Áú
  • metabolic antagonist
    ´ë»ç ±æÇ×Á¦
  • narcotic antagonist
    ¸¶¾à ±æÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±Ù ±æÇ×Á¦
  • pyrimidine antagonist
    ÇǸ®¹Ìµò ±æÇ×Á¦
  • serotonin antagonist
    ¼¼·ÎÅä´Ñ ±æÇ×Á¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
receptors, leukotriene Cell-surface receptors that bind leukotrienes with high affinity and trigger intracellular changes influencing the behaviour of cells. The leukotriene receptor subtypes have been tentatively named according to their affinities for the endogenous leukotrienes ltb4, ltc4, ltd4, and lte4.
(12 Dec 1998)
receptors, leukotriene b4 A class of cell surface leukotriene receptors with a preference for leukotriene b4. Leukotriene b4 receptor activation influences chemotaxis, chemokinesis, adherence, enzyme release, oxidative bursts, and degranulation in polymorphonuclear leukocytes. There are at least two subtypes of these receptors. Some actions are mediated through the inositol phosphate and diacylglycerol second messenger systems.
(12 Dec 1998)
leukotriene Any of a group of hormonesderived from arachidonate (arachidonic acid).They are thought to mediate the allergic response that causes lungconstriction and muscle contraction in asthma.
(09 Oct 1997)
leukotriene a4 (2s-(2 alpha,3 beta(1e,3e,5z,8z)))-3-(1,3,5,8-tetradecatetraenyl)oxiranebutanoic acid. An unstable allylic epoxide, formed from the immediate precursor 5-hpete via the stereospecific removal of a proton at c-10 and dehydration. Its biological actions are determined primarily by its metabolites, i.e., leukotriene b4 and cysteinyl-leukotrienes. Alternatively, leukotriene a4 is converted into leukotriene c4 by glutathione-s-transferase or into 5,6-di-hete by the epoxide-hydrolase.
(12 Dec 1998)
leukotriene A4 hydrolase <enzyme> Catalyses hydrolysis of leukotriene a4 to leukotriene b4; mw 68,000-70,000
Registry number: EC 3.3.2.-
Synonym: leukotriene a4 aminopeptidase
(26 Jun 1999)
leukotriene b4 <chemical> (s-(r*,s*-(e,z,e,z)))-5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid. The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centreed free radicals, arachidonic acid release, and metabolism).
Chemical name: 6,8,10,14-Eicosatetraenoic acid, 5,12-dihydroxy-, (S-(R*,S*-(E,Z,E,Z)))-
(12 Dec 1998)
leukotriene B4 12-hydroxydehydrogenase <enzyme> Catalyses the oxidation of leukotriene b4 to 12-oxoleukotriene b4
Registry number: EC 1.1.1.-
Synonym: ltb4 12-hydroxydehydrogenase, ltb(4) 12-hydroxydehydrogenase
(26 Jun 1999)
leukotriene B4 6-isomerase <enzyme> From rat kidney homogenates
Registry number: EC 5.2.-
(26 Jun 1999)
leukotriene B4 reductase <enzyme> Converts leukotriene b4 (5s,12r-dihydroxyeicosoletra-6,8,10,14-enoic acid) to dihydro ltb4 (5s,12r-10,11-dihydroeicosatri-6,8,14-enoic acid), requires NADPH, ca and mg
Registry number: EC 1.3.1.-
(26 Jun 1999)
leukotriene c4 <chemical> (r-(r*,s*-(e,e,z,z))))-n-(s-(1-(4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-n-l-gamma-glutamyl-l-cysteinyl)glycine. The conjugation product of leukotriene a4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitised lung tissue. It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some vascular smooth muscle.
Chemical name: Glycine, N-(S-(1-(4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-N-L-gamma-glutamyl-L-cysteinyl)-, (R-(R*,S*-(E,E,Z,Z)))-
(12 Dec 1998)
leukotriene-C4 synthase <enzyme> From particulate fraction of rat basophil leukaemia homogenates; not sensitive to inhibitors of most soluble glutathione s-transferases
Registry number: EC 2.5.1.37
Synonym: leukotriene c synthase, leukotriene a4-glutathione s-leukotrienyltransferase, leukotriene c4 synthetase, glutathione s-transferase II, gst-ii
(26 Jun 1999)
leukotriene d4 <chemical> (r-(r*,s*-(e,e,z,z)))-n-(s-(1-(4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-l-cysteinyl)glycine. One of the biologically active principles of srs-a. It is generated from leukotriene c4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability.
Chemical name: Glycine, N-(S-(1-(4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-L-cysteinyl)-, (R-(R*,S*-(E,E,Z,Z)))-
(12 Dec 1998)
leukotriene D4 dipeptidase <enzyme> Converts leukotriene d4 to leukotriene e4
Registry number: EC 3.4.13.-
Synonym: ld4 dipeptidase
(26 Jun 1999)
leukotriene e4 <chemical> (5s-(5r*,6s*(s*),7e,9e,11z,14z))-6-((2-amino-2-carboxyethyl)thio)-5-hydroxy-7,9,11,14-eicosatetraenoic acid. A biologically active principle of srs-a that is formed from leukotriene d4 via a peptidase reaction that removes the glycine residue. The biological actions of lte4 are similar to ltc4 and ltd4.
Chemical name: 7,9,11,14-Eicosatetraenoic acid, 6-((2-amino-2-carboxyethyl)thio)-5-hydroxy-, (5S-(5R*,6S*(S*),7E,9E,11Z,14Z))-
(12 Dec 1998)
aldosterone antagonist An agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents, e.g., spironolactone, are useful in treating the hypertension of primary hyperaldosteronism, or the sodium retention of secondary hyperaldosteronism.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    Àû´ë
  • antagonist
    Àû´ëÀÚ;´ë¸³ÀÚ
  • receptor
    ¼ö¿ë±â;°¨°¢±â°ü;¼ö¿ëü
  • receptor site
    ¼¼Æ÷³» ¼ö¿ë ¿µ¿ª
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á